Eagle Asset Management Inc Fate Therapeutics Inc Transaction History

Eagle Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $79,106 - $191,188	8,023 Added 2.18%	376,460 $3.8 Million
Q3 2022 Nov 07, 2022	BUY	$21.04 - $36.06 $2.86 Million - $4.89 Million	135,735 Added 58.33%	368,437 $8.26 Million
Q2 2022 Aug 10, 2022	BUY	$17.78 - $42.39 $91,140 - $217,291	5,126 Added 2.25%	232,702 $5.77 Million
Q1 2022 May 12, 2022	BUY	$29.67 - $60.28 $362,923 - $737,344	12,232 Added 5.68%	227,576 $8.82 Million
Q4 2021 Feb 11, 2022	SELL	$47.84 - $64.34 $2.1 Million - $2.82 Million	-43,792 Reduced 16.9%	215,344 $12.9 Million
Q3 2021 Nov 10, 2021	SELL	$59.27 - $95.73 $807,850 - $1.3 Million	-13,630 Reduced 5.0%	259,136 $15.4 Million
Q2 2021 Aug 11, 2021	SELL	$67.25 - $92.52 $977,075 - $1.34 Million	-14,529 Reduced 5.06%	272,766 $23.7 Million
Q1 2021 May 14, 2021	BUY	$72.16 - $117.4 $20.7 Million - $33.7 Million	287,295 New	287,295 $23.5 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.